| | | | |
CUSIP No. 50736W105 | | 13D | | Page 9 of 10 Pages |
On April 28, 2022, the Founders entered into a new consortium agreement (the “Consortium Agreement”) with Tenzing Holdings 2011 Ltd. and Sino Avenue Limited, pursuant to which the Founders, Tenzing Holdings 2011 Ltd. and Sino Avenue Limited (collectively, the “Buyer Group”) agreed to jointly undertake an acquisition transaction to acquire all of the outstanding Ordinary Shares of the Company other than those Ordinary Shares beneficially owned by the Buyer Group, through a going-private transaction (the “Proposed Transaction”). The Consortium Agreement provides, among other things, for cooperation and participation in the evaluation of the Company, discussions regarding the Revised Proposal (as defined below) with the Company, and negotiation of the terms of definitive documentation in connection with the Proposed Transaction. The Consortium Agreement also provides that, for a period beginning on the date of the Consortium Agreement and ending on the earlier of (i) the 6-month anniversary after such date, and (ii) the termination of the Consortium Agreement pursuant to certain terms thereof, the Buyer Group members shall work exclusively with each other to implement the Proposed Transaction.
Also on April 28, 2022, the Buyer Group submitted a revised non-binding proposal (the “Revised Proposal”) to the special committee of the Board to reaffirm its interests in the Proposed Transaction and revise the offer price to US$ 1.90 per ADS or US$ 0.1357 per Ordinary Share in cash.
The Proposed Transaction is subject to a number of conditions, including, among other things, the negotiation and execution of definitive agreements mutually acceptable in form and substance to the Company and the Buyer Group. Neither the Company nor the Buyer Group is obligated to complete the Proposed Transaction, and a binding commitment with respect to the Proposed Transaction will result only from the execution of definitive documents, and then will be on the terms provided in such documentation.
If the Proposed Transaction is completed, the Company’s ADSs would become eligible for termination of registration pursuant to Section 12(g)(4) of the Act and would cease to be quoted on the OTC Market.
References to the Termination Agreement, the Consortium Agreement and the Revised Proposal in this Schedule 13D are qualified in their entirety by reference to the Termination Agreement, the Consortium Agreement and the Revised Proposal, a copy of which is attached hereto as Exhibit D, Exhibit E and Exhibit F, respectively, and incorporated herein by reference in its entirety.
Except as indicated above, the Reporting Persons have no plans or proposals which relate to or would result in any of the actions specified in paragraphs (a) through (j) of Item 4 of Schedule 13D.
Item 5. Interest in Securities of the Issuer.
Item 5(a)–(d) of the Schedule 13D is hereby amended and restated by the following:
(a)–(b) The responses of each Reporting Person to Rows (7) through (13), including the footnotes thereto, of the cover pages of this Schedule 13D are hereby incorporated by reference in this Item 5.
Except as otherwise stated herein, each Reporting Person expressly disclaims any beneficial ownership of the Ordinary Shares held by each other Reporting Person.
(c) Except as disclosed in this Schedule 13D, none of the Reporting Persons has effected any transaction in the Ordinary Shares during the past 60 days.
(d) Except as disclosed in this Schedule 13D, to the best knowledge of the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Ordinary Shares beneficially owned by any of the Reporting Persons.
9